Abstract:As normal tissues contain normal tissue stem cells (NSCs), tumors are thought to contain tumor stem cells (TSCs) which perform self-renewal and generate their progenies. TSC can be a therapeutic target; however, cancer therapies targeting TSCs are limited, because most of the TSC markers are shared by NSCs. Therefore, it is important to identify TSC-specific markers. Previously, we reported that doublecortin-like kinase 1 (Dclk1)-positive epithelial cells do not produce any progenies in the normal small intestine but supply progeny tumor cells in the tumors of Apc mice. Selective ablation of Dclk1-positive TSCs collapses the intestinal tumors of Apc mice. Therefore, Dclk1 appears to be a specific marker of TSCs in the mouse intestinal tumors. In the present study, we performed microarray analysis in order to investigate the characteristics of Dclk1-positive TSCs in the tumors of Apc mice. Dclk1-positive tumor cells had higher expression levels of cyclooxygenase 1 (Cox1), leukotriene C4 synthase (Ltc4s), and arachidonate 5-lipoxygenase activating protein (Alox5ap) than Dclk1-negative cells in the tumors of Apc mice, suggesting that Dclk1positive cells in the tumors of Apc mice had higher expression levels of the genes which were related to prostaglandin and leukotriene metabolism. As well, microarray analysis revealed that gustducin alpha and gamma subunits, transient receptor potential cation channel, subfamily M, member 5 (TRPM5), and phospholipase C beta 2 were more highly expressed in Dclk1-positive tumor cells. Thus, Dclk1-positive tumor cells seemed to possess the characteristic of Tuft cells. Furthermore, Dclk1-positive tumor cells had higher expression level of Ras-related C3 botulinum toxin substrate 2 (Rac2) than Dclk1-negative tumor cells in Apc mouse intestine. In order to elucidate the role of Rac2 in Dclk1-positive TSCs, we generated tumor spheroids from Apc mouse tumors, and administrated EHT1864, Rac inhibitor to the spheroids. Following 5-day treatment with EHT1864, the growth of the tumor spheroids was significantly suppressed. Importantly, on day1, EHT1864 treatment significantly reduced the proportion of Dclk1-positive cells in the tumor spheroids. These results suggested that Rac2 played some roles for the maintenance of the intestinal tumor spheroids. In conclusion, this study may provide new insights into the maintenance mechanisms of Dclk1-positive TSC in the intestinal tumors, and give us hints to develop novel therapeutic strategies targeting TSCs against colorectal cancers.

Cyclin D1 Inhibits Whereas C-Myc Enhances the Cytotoxicity of Cisplatin in Mouse Pancreatic Cancer Cells Via Regulation of Several Members of the NF-κB and Bcl-2 Families.

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

Su2005 DCLK1 Promotes Pancreatic Cancer Cell Clonogenicity and Invasiveness

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

[Inhibition Effect on Tca8113/CDDP by Antisense Oligonucleotides of Cyclin D1 Combined with Cis Diamminedichloroplatinum].

Inhibition of Cyclin D1 Expression by Cyclin D1 Shrnas in Human Oral Squamous Cell Carcinoma Cells is Associated with Increased Cisplatin Chemosensitivity.

Inhibition of MYC Suppresses Programmed Cell Death Ligand-1 Expression and Enhances Immunotherapy in Triple-Negative Breast Cancer

c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer

Cyclin C Promotes Pancreatic Development and Suppresses Cancer Initiation Through Maintenance of the Autophagy-Lysosome Pathway

Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1

Differential Regulation of C-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer Cells

MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation

Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma

Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma

Cytoplasmic P21 Induced by P65 Prevents Doxorubicin-Induced Cell Death in Pancreatic Carcinoma Cell Line

The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells

Ubiquitylation of cyclin C by HACE1 regulates cisplatin‐associated sensitivity in gastric cancer

Cisplatin Pretreatment Enhances Anti-Tumor Activity of Cytokine-Induced Killer Cells

Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells